Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  International Journal of Cardiology

• Publication date

  2005-04-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.IJCARD.2004.07.014PMID 15820288
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• UvA-DARE ( Digital Academic Repository ) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina : the CAPTURE study

  2017cited by this paper
• Benefits and Safety of Tirofiban Among Acute Coronary Syndrome Patients With Mild to Moderate Renal Insufficiency: Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial

  2002cited by this paper
• Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.

  2002cited by this paper
• Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.

  2002cited by this paper
• Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.

  2002cited by this paper
• Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.

  2001cited by this paper
• Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961

  2000cited by this paper
• Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.

  2000cited by this paper
• Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.

  2000cited by this paper
• Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome

  2000cited by this paper
• Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

  1999cited by this paper
• Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

  1999cited by this paper
• Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

  1998cited by this paper
• A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

  1998cited by this paper
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

  1998cited by this paper
• Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide

  1998cited by this paper
• A novel method of assessing regurgitant severity: time and spatial integration of cross-sectional color doppler energy images

  1998cited by this paper
• Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.

  1998cited by this paper
• Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

  1998cited by this paper
• Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.

  1997cited by this paper
• Primary and secondary safety endpoints from IMPACT II

  1997cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

  1997cited by this paper
• Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.

  1997cited by this paper
• Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.

  1996cited by this paper
• Impaired high‐shear‐stress‐induced platelet aggregation in patients with chronic renal failure undergoing haemodialysis

  1995cited by this paper
• Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators.

  1995cited by this paper
• Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance.

  1995cited by this paper
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

  1994cited by this paper
• Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease.

  1994cited by this paper
• Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.

  1991cited by this paper
• Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.

  1987cited by this paper

• Acute profound thrombocytopenia induced by tirofiban in stent assisted embolization of intracranial ruptured aneurysm-a rare case report.

  2023cites this paper
• Case report: reuse of tirofiban leads to very severe thrombocytopenia

  2023cites this paper
• Clinical pharmacology of antiplatelet drugs

  2022cites this paper
• Predictive value of the age, creatinine and ejection fraction score in patients undergoing primary percutaneous coronary intervention with bail-out tirofiban therapy

  2021cites this paper
• Analysis of Bleeding Complications in Acute Coronary Syndrome: Comparison of Effect of Tirofiban in Diabetic and Non-Diabetic Patients

  2018cites this paper
• Gender differences in the association between discharge hemoglobin and 12‐month mortality after acute myocardial infarction

  2017cites this paper
• A Novel Pentapeptide Targeting Integrin β3-Subunit Inhibits Platelet Aggregation and Its Application in Rat for Thrombosis Prevention

  2016cites this paper
• Tirofiban induced anemia without thrombocytopenia.

  2015cites this paper
• Patients undergoing PCI from the femoral route by default radial operators are at high risk of vascular access-site complications.

  2014cites this paper
• Antiplatelet agents for chronic kidney disease.

  2013cites this paper
• Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review

  2012cites this paper
• Comparison of short- and long- term haemostatic compression after transradial procedures

  2012cites this paper
• Iron deficiency activates pro-inflammatory signaling in macrophages and foam cells via the p38 MAPK-NF-κB pathway.

  2011cites this paper
• Comparison of short-and long term compression after transradial coronary procedures

  2011cites this paper
• Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the CRUSADE initiative

  2011cites this paper
• Effect of tirofiban on short-term prognosis of elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention: Effect of tirofiban on short-term prognosis of elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention

  2011cites this paper
• Bleeding complications associated with glycoprotein IIb/IIIa inhibitors in patients 80 years of age and older undergoing percutaneous coronary intervention.

  2010cites this paper
• A risk score to predict bleeding in patients with acute coronary syndromes.

  2010cites this paper
• Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative.

  2010cites this paper
• Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes

  2009cites this paper
• Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]).

  2009cites this paper
• Guidelines to practice gap in the use of glycoprotein IIb/IIIa inhibitors: from ISAR-REACT to overreact?

  2009cites this paper
• Acute Coronary Syndrome in Women and the Elderly

  2008cites this paper
• Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia

  2007cites this paper
• Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.

  2007cites this paper
• Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment.

  2007cites this paper
• Compression of the left main coronary artery by the pulmonary artery in a patient with the Eisenmenger syndrome.

  2007cites this paper
• Comparison of access-related bleeding complications in women versus men undergoing percutaneous coronary catheterization using the radial versus femoral artery.

  2007cites this paper
• Adjunctive pharmacotherapy for coronary interventions—time to read the writing on the wall

  2006cites this paper
• Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors: Results From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative

  2006cites this paper
• Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.

  2006cites this paper
• INTERVIEW THE ROLE OF DIRECT THROMBIN INHIBITORS IN THE FUTURE OF HEALTHCARE — Interview with Ann

  2005cites this paper
• Registration of antithrombotic policy for the management of acute coronary syndromes in the Greek population.

  2005cites this paper